Alnylam Turns To Value-Based Pricing Again For Oxlumo
As with its first two approved RNAi therapies, Alnylam will negotiate value-based agreements with payers, but for Oxlumo, approved in pediatric patients, it will offer a patient need adjustment.
You may also be interested in...
Founding CEO will remain involved with Alnylam’s scientific advisory board, while current president/COO Yvonne Greenstreet will move up to the chief executive’s office.
EcoR1 and Casdin/Corvex took their second and third special purpose acquisition corporations public. Also, Ionis sold notes to buy back older notes and fund operations as it cut 70% of Akcea’s staff. In venture capital, ValenzaBio raised $70m and RA boosted Metagenomi’s series A to $75m.
When Greene made the decision to leave Alnylam, he was interested in working with a drug maker treating central nervous system diseases.